NRx Pharmaceuticals (NRXP) Q4 2024 earnings summary

Executive summary

• Transitioned from R&D to a revenue-generating healthcare model, aiming for profitability by end of 2025.

• Raised new capital, retired toxic debt, and established Hope Therapeutics as a wholly-owned subsidiary focused on clinical care.

• Advanced NDA filings for NRX-100 (preservative-free ketamine) and NRX-101 (oral combination for bipolar depression), both with anticipated PDUFA dates before Dec 31, 2025.

• Signed non-binding letters of intent to acquire profitable interventional psychiatry clinics, with a focus on Florida and national expansion.

• Regained NASDAQ compliance and substantially reduced operating costs year-over-year.

Financial highlights

• Reduced loss from operations by $9.3 million (33.5%) to $18.5 million for 2024, compared to $27.8 million in 2023.

• Q4 2024 loss from operations reduced to $2.4M from $4.4M in Q4 2023, a 45% improvement, mainly due to lower R&D costs and a settlement gain.

• Research and development expense decreased by $7.2 million (53.6%) to $6.2 million, mainly due to the conclusion of a major clinical trial.

• General administrative expense decreased by $7.7 million to $13.5 million, driven by lower insurance and employee costs.

• Ended 2024 with $1.4 million in cash; raised an additional $8.5 million in January 2025, extending runway through at least end of 2025.

Outlook and guidance

• Forecasting profitability on a run-rate basis by end of 2025, driven by Hope Therapeutics revenue and projected drug sales.

• Anticipates 2025 PDUFA dates for both NRX-100 and NRX-101 NDAs.

• Plans to file an ANDA for preservative-free ketamine in 2Q25 and expand Hope Therapeutics to 15-20 clinics in Florida by year-end 2025.

• Plans to spin out Hope Therapeutics to shareholders in a tax-free manner once conditions allow.